Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide versus placebo added to basal insulin in type 2 diabetes
NL-OMON37485Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Liraglutide add-on arm with Placebo add-on arm (2 arms). Primary endpoint: Change in HbA1c from baseline to week 26. Started Sep 2012; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON37485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37485.